ERYTHROCYTE POLYAMINES AND PROGNOSIS IN STAGE D2 PROSTATIC-CARCINOMA PATIENTS

被引:20
作者
CIPOLLA, B [1 ]
GUILLE, F [1 ]
MOULINOUX, JP [1 ]
BANSARD, JY [1 ]
ROTH, S [1 ]
STAERMAN, F [1 ]
CORBEL, L [1 ]
QUEMENER, V [1 ]
LOBEL, B [1 ]
机构
[1] CTR HOSP REG & UNIV RENNES,RECH TERAPEUT ANTICANCEREUSE GRP,RENNES,FRANCE
关键词
ANTIGENS; NEOPLASM; PROSTATIC NEOPLASMS; BIOGENIC POLYAMINES; ERYTHROCYTES; PROGNOSIS;
D O I
10.1016/S0022-5347(17)35033-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
We studied 43 patients with newly diagnosed, untreated, stage D2 prostatic carcinoma, and correlated the initial performance status, hemoglobin, prostate specific antigen levels, tumor Gleason grade, extent of disease on the bone scan, and erythrocyte spermidine and spermine levels with progression. Three patients died of unrelated causes and were excluded from the study, 16 remained in remission with a mean 28 +/- 11 months of followup and 24 had progression (18, or 75%, of whom died of the cancer) with a mean 12 +/- 9 months of followup (p < 0.05 for followup) after initiation of hormonal therapy. Pretreatment performance status, hemoglobin, and erythrocyte spermidine and spermine levels were correlated with progression, hemoglobin and spermine being the most significant independent variables (p = 0.006 and p = 0.001, respectively). Concerning cause-specific survival, only hemoglobin and spermine erythrocyte levels were significant independent variables (p = 0.02 and p = 0.0025, respectively). If confirmed, polyamine erythrocyte levels obtained by a simple blood sample could discriminate at diagnosis patients with a high risk of rapid hormonal relapse who may benefit from a more aggressive primary management.
引用
收藏
页码:629 / 633
页数:5
相关论文
共 41 条
  • [11] GLEASON DF, 1978, UROLOGIC PATHOLOGY P, P171
  • [12] CARCINOMA OF THE PROSTATE - RELATIONSHIP OF PRETREATMENT HORMONE LEVELS TO SURVIVAL
    HARPER, ME
    PIERREPOINT, CG
    GRIFFITHS, K
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1984, 20 (04): : 477 - 482
  • [13] ISAACS JT, 1988, PROSTATE, V13, P165
  • [14] POLYAMINES IN RAPID GROWTH AND CANCER
    JANNE, J
    POSO, H
    RAINA, A
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1978, 473 (3-4) : 241 - 293
  • [15] KUBO M, 1988, Mie Medical Journal, V38, P283
  • [16] Moulinoux J P, 1988, Adv Exp Med Biol, V250, P353
  • [17] THE GROWTH OF MAT-LYLU RAT PROSTATIC ADENOCARCINOMA CAN BE PREVENTED INVIVO BY POLYAMINE DEPRIVATION
    MOULINOUX, JP
    QUEMENER, V
    CIPOLLA, B
    GUILLE, F
    HAVOUIS, R
    MARTIN, C
    LOBEL, B
    SEILER, N
    [J]. JOURNAL OF UROLOGY, 1991, 146 (05) : 1408 - 1412
  • [18] RED-BLOOD-CELL POLYAMINES IN MICE BEARING THE LEWIS LUNG-CARCINOMA (3LL) AND IN PATIENTS WITH BRONCHOPULMONARY CANCERS
    MOULINOUX, JP
    QUEMENER, V
    LARZUL, JJ
    LECALVE, M
    ROCH, AM
    TOUJAS, L
    QUASH, G
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1984, 34 (02) : 277 - 281
  • [19] DIAGNOSTIC VALUE OF ERYTHROCYTE-FREE POLYAMINES AND HISTAMINEMIA IN MALIGNANT HEPATIC-TUMORS AND IN LIVER-CIRRHOSIS
    MOULINOUX, JP
    DELAMAIRE, D
    BEAU, B
    QUEMENER, V
    BRISSOT, P
    LECALVE, M
    DEUGNIER, Y
    CHAMBON, Y
    BOUREL, M
    [J]. CLINICA CHIMICA ACTA, 1985, 145 (01) : 77 - 87
  • [20] EVOLUTION OF RED-BLOOD-CELL POLYAMINE LEVELS IN PARTIALLY HEPATECTOMIZED RAT
    MOULINOUX, JP
    QUEMENER, V
    CHAMBON, Y
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (02): : 237 - 244